DNTH - NASDAQ
Dianthus Therapeutics, Inc.
$84.97
-1.5%Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
At a Glance
Live SnapshotDianthus Therapeutics, Inc. Management Team
Mr. Edward G. Carr
Chief Accounting Officer
Mr. Ryan Savitz
Chief Financial Officer & Chief Business Officer
Compensation
$655,479
Mr. Simrat Randhawa M.B.A., M.D.
Chief Medical Officer
Compensation
$688,600
Ms. Kristina Maximenko
Chief People Officer
Mr. Scott Nogi M.B.A.
Head of Business Operations
Ms. Rashieda Gluck
Head of Clinical Development Operations
Mr. Marino Garcia M.B.A.
President, Chief Executive Officer & Director
Compensation
$943,800
Mr. Judson Taylor
Senior Vice President & Head of Technical Operations
Mr. Adam M. Veness Esq.
Senior Vice President, General Counsel & Secretary
Ms. Jennifer Davis Ruff
Vice President and Head of Investor Relations & Corporate Affairs.
Dianthus Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $9.44M and sold $8.89M worth of DNTH shares, resulting in $545K of net buying activity.
3 Months
0
0.00
86.7K
7.05M
-7.1M
-$7.05M
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
260.0K
9.44M
46.2K
1.84M
+7.6M
+$7.59M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Garcia Marino
Director, Officer: Ceo And President
$4.72M
Savitz Ryan
Officer: Cfo & Cbo
$2.44M
Randhawa Simrat
Officer: Chief Medical Officer
$2.27M
Top Sellers
Garcia Marino
Director, Officer: Ceo And President
$3.51M
Soteropoulos Paula
Director
$2.20M
Savitz Ryan
Officer: Evp, Cfo & Cbo
$1.75M
Randhawa Simrat
Officer: Evp, Head Of R&D
$1.42M
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $545K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
SEC Filings
DNTH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 09, 2026 | May 21, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 10, 2025 | May 22, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 11, 2024 | May 23, 2024 | 2024 | |
DEF 14A DEF 14A 2022 N/A | May 02, 2022 | June 28, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 21, 2021 | June 01, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 24, 2020 | June 05, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 25, 2019 | June 07, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.